Display options
Cite
Meece JD, Pearson TL, Siminerio LM. Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action. Diabetes Educ. 2014;40(1):4S-26Sdoi: 10.1177/0145721714527802.
Meece, J. D., Pearson, T. L., & Siminerio, L. M. (2014). Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action. The Diabetes educator, 40(1), 4S-26S. https://doi.org/10.1177/0145721714527802
Meece, Jerry D, et al. "Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action." The Diabetes educator vol. 40,1 (2014): 4S-26S. doi: https://doi.org/10.1177/0145721714527802
Meece JD, Pearson TL, Siminerio LM. Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action. Diabetes Educ. 2014 May 01;40(1):4S-26S. doi: 10.1177/0145721714527802. Epub 2014 May 19. PMID: 24841710.
Copy Download .nbib Format: NLM
Share it on

Diabetes Educ. 2014 May 01;40(1):4S-26S. doi: 10.1177/0145721714527802. Epub 2014 May 19.

Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action.

The Diabetes educator

Jerry D Meece, Teresa L Pearson, Linda M Siminerio

Affiliations

  1. Plaza Pharmacy and Wellness Center, Gainesville, Texas (Mr Meece)
  2. Halleland Habicht Consulting, LLC, Minneapolis, Minnesota (Ms Pearson)
  3. University of Pittsburgh, Diabetes Institute, Pittsburgh, Pennsylvania (Dr Siminerio)

PMID: 24841710 DOI: 10.1177/0145721714527802

Abstract

PURPOSE: The use of insulin and incretin-based therapies together has recently emerged as a new therapeutic option for patients with type 2 diabetes. This approach can be used across the continuum of diabetes and is supported by clinical trial evidence. To illustrate how these data may apply to clinical care, this supplement uses patient case studies to provide clinical context for diabetes educators. Relevant medical literature was searched and cited. Search terms included insulin, DPP-4 inhibitors, GLP-1 receptor agonists, hypoglycemia, and weight gain.

CONCLUSION: Insulin remains the most potent glucose-lowering agent available for the treatment of type 2 diabetes but has limitations, primarily of hypoglycemia and secondarily of weight gain. The addition of incretin-based therapies complements the glucose-lowering potential of basal insulin, without increasing the risk of hypoglycemia, potentially allowing for lower doses of insulin and without increasing weight gain (DPP-4 inhibitors) or possibly with weight loss (GLP-1 receptor agonists). Incretin-based therapies offer advantages over prandial insulin to address postprandial hyperglycemia.

© 2014 The Author(s).

Publication Types